Table 2.

Histopathological features

IDDurationInsulin+ isletsCD8+ cells/islet (islets counted)Islet HLA class I (pattern)Tetramer reactivitya (pattern)
%
Recent onset cases
    Patient A<1 wkIsolated cells only8.8 (160)PositiveInsulin, IGRP (monospecific)
    Patient B1 wkNone8.4 (125)PositiveInsulin, IGRP (monospecific)
    Patient C10 wkPartial loss<1 (128)PositiveHLA-mismatched control (no staining)
    Patient D6 mo253.5 (116)PositiveInsulin
    Patient E9 mo504.1 (150)PositiveInsulin
Longstanding cases
    Patient 11 yr<503.2 (140)PositiveIGRP
    Patient 21 yr104.3 (40)PositiveIGRP, IA-2, insulin (mono-/multispecific)
    Patient 33 yr151.5 (70)PositiveNo staining
    Patient 43 yr396.5 (20)PositiveIGRP, GAD65, ppIAPP, insulin (multispecific)
    Patient 57 yr709.4 (30)Positive (tail region only)IGRP, GAD65, PPI, insulin, IA-2 (mono-/multispecific)
    Patient 68 yr703.5 (20)Positive (lobular)No staining
  • a patients A, B, C, D, E, 1, and 3 were stained for reactivity against IGRP, insulin, and PPI in Siena. Patients 2, 4, 5, and 6 were stained for reactivity against IGRP, insulin, PPI, IA-2, GAD65, and ppIAPP in La Jolla.